Table 5.
Comparison of IFN-γ ELISPOT assay and T-SPOT.TB assay with 86 PTB samplesb
| Assay and peptides | No. of positive samples | Positivity rate (%) | SFP value (SFC/106 PBMCs or viable cells)a |
||
|---|---|---|---|---|---|
| P25 | P50 | P75 | |||
| IFN-γ ELISPOT assay | |||||
| E6+E7 | 76 | 88.37 | 170 | 754 | 1450 |
| E6+E7+C14 | 81 | 94.19 | 160 | 733 | 1539 |
| Total of E6+E7 and E6+E7+C14 | 83 | 96.51 | 165 | 740 | 1456 |
| T-SPOT.TB assay | |||||
| Panel A | 83 | 96.51 | 66 | 154 | 344 |
| Panel B | 84 | 97.67 | 86 | 271 | 894 |
| Total of panel A and panel B | 85 | 98.84 | 66 | 246 | 801 |
P25, lower quartile SFP value; P50, median SFP value; P75, upper quartile SFP value.
All detection assays had a high sensitivity. A Wilcoxon test was used to analyze the difference between IFN-γ ELISPOT assay and T-SPOT.TB assay. It was found that the median SFP value for E6+E7 (or E6+E7+C14) was higher than that for panel A (P < 0.05), and that for the total of E6+E7 and E6+E7+C14 was higher than that for the total of panel A and panel B. No significant differences were found between E6+E7 (or E6+E7+C14) and panel B (P > 0.05); on the other hand, similar positive detection rates were found for E6+E7+C14 and panels A and B and for the total of E6+E7 and E6+E7+C14 and the total of panel A and panel B (P > 0.05), but the positive detection rate was lower with E6+E7 than with panel A and panel B (P < 0.05).